Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 3/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.32 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.31 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 3/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.31 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4474577 | 1.00 | ADRB3 (0.39) | ADRB3AOC3MEN1KMT2AMAPT | |
| SCHEMBL6244465 | 0.90 | LPAR1 (0.36) | ADRB3AOC3MEN1KMT2AMAPT | |
| SCHEMBL4468537 | 0.88 | ADRB3 (0.44) | ADRB3AOC3LPAR1LPAR5ADRB1 | |
| SCHEMBL4468542 | 0.88 | ADRB3 (0.44) | ADRB3AOC3LPAR1LPAR5ADRB1 | |
| SCHEMBL1622477 | 0.84 | BACE1 (0.43) | ADRB3BACE1ADRB1 | |
| SCHEMBL4462454 | 0.84 | BACE1 (0.43) | ADRB3BACE1ADRB1 | |
| SCHEMBL5950226 | 0.84 | AOC3 (0.35) | ADRB3AOC3KDM4EBACE1CPB2 | |
| SCHEMBL7716904 | 0.83 | AOC3 (0.36) | ADRB3AOC3MEN1KMT2ABACE1 | |
| SCHEMBL5949849 | 0.82 | AOC3 (0.36) | AOC3ITGB1ITGA4BACE1CPB2 | |
| SCHEMBL6437304 | 0.82 | AOC3 (0.36) | AOC3ITGB1ITGA4BACE1CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629366-B2 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-08 | — | — | US | disclosed |
| US-20060100252-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-7037938-B2 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2006-05-02 | — | — | US | disclosed |
| US-20040006143-A1 | For therapy of urinary incontinence | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100252-A1 | Aminoalcohol derivatives | H1-0, CHRM2, CHRM1 | ADRB3 130/4885AOC3 1124/4885MEN1 4134/4885 |
| US-20040006143-A1 | For therapy of urinary incontinence | H1-0, HRH2, H1-2 | ADRB3 568/4885AOC3 1109/4885MEN1 4292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.